Abstract:Huntington's disease (HD) is an autosomal dominant neurodegenerative disease caused by a single mutation in the huntingtin gene (HTT). Normal HTT has a CAG trinucleotide repeat at its N-terminal within the range of 36. However, once the CAG repeats exceed 37, the mutant gene (mHTT) will encode mutant HTT protein (mHTT), which results in neurodegeneration in the brain, specifically in the striatum and other brain regions. Since the mutation was discovered, there have been many research efforts to understand the mechanism and develop therapeutic strategies to treat HD. HTT is a large protein with many post-translational modification sites (PTMs) and can be modified by phosphorylation, acetylation, methylation, sumoylation, etc. Some modifications reduced mHTT toxicity both in cell and animal models of HD. We aimed to find the known kinase inhibitors that can modulate the toxicity of mHTT. We performed an in vitro kinase assay using HTT peptides, which bear different PTM sites identified by us previously. A total of 368 kinases were screened. Among those kinases, cyclin-dependent kinases (CDKs) affected the serine phosphorylation on the peptides that contain S1181 and S1201 of HTT. We explored the effect of CDK1 and CDK5 on the phosphorylation of these PTMs of HTT and found that CDK5 modified these two serine sites, while CDK5 knockdown reduced the phosphorylation of S1181 and S1201. Modifying these two serine sites altered the neuronal toxicity induced by mHTT. Roscovitine, a CDK inhibitor, reduced the p-S1181 and p-S1201 and had a protective effect against mHTT toxicity. We further investigated the feasibility of the use of roscovitine in HD mice. We confirmed that roscovitine penetrated the mouse brain by IP injection and inhibited CDK5 activity in the brains of HD mice. It is promising to move this study to in vivo for pre-clinical HD treatment.

Suppression of MAPK11 or HIPK3 Reduces Mutant Huntingtin Levels in Huntington's Disease Models

HAP40 is a conserved central regulator of Huntingtin and a specific modulator of mutant Huntingtin toxicity

HIPK3 Modulates Autophagy and HTT Protein Levels in Neuronal and Mouse Models of Huntington Disease

Inhibition of HIPK3 by AST487 Ameliorates Mutant HTT-Induced Neurotoxicity and Apoptosis Via Enhanced Autophagy

HAP40 Modulates Mutant Huntingtin Aggregation and Toxicity in Huntington’s Disease Mice

HAP40 modulates mutant Huntingtin aggregation and toxicity in Huntington's disease mice

Enhancement of Brain-Type Creatine Kinase Activity Ameliorates Neuronal Deficits in Huntington's Disease

An insight into allele-selective approaches to lowering mutant huntingtin protein for Huntington's disease treatment

Lowering mutant huntingtin by small molecules relieves Huntington’s disease symptoms and progression

Protective role of downregulation in Huntington’s Disease models

Allele-selective lowering of mutant HTT protein by HTT–LC3 linker compounds

Loss of Hap1 Selectively Promotes Striatal Degeneration in Huntington Disease Mice

NUB1 Suppression of Huntington Toxicity: Mechanistic Insights

Roscovitine, a CDK Inhibitor, Reduced Neuronal Toxicity of mHTT by Targeting HTT Phosphorylation at S1181 and S1201 In Vitro

Discovery of an Autophagy Inducer J3 to Lower Mutant Huntingtin and Alleviate Huntington’s Disease-Related Phenotype

Ablation Of Huntingtin In Adult Neurons Is Nondeleterious But Its Depletion In Young Mice Causes Acute Pancreatitis

Regulation of Feedback Between Protein Kinase A and the Proteasome System Worsens Huntington's Disease.

CRISPR/Cas9-mediated Gene Editing Ameliorates Neurotoxicity in Mouse Model of Huntington’s Disease

Suppression of Huntington's Disease Somatic Instability by Transcriptional Repression and Direct CAG Repeat Binding

Preventing mutant huntingtin proteolysis and intermittent fasting promote autophagy in models of Huntington disease

TRIM37 is a Primate-Specific E3 Ligase for Huntingtin and Accounts for the Striatal Degeneration in Huntington’s Disease